Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREW POKLEPOVIC

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1356550800
CMS profile
515912
Location
RICHMOND, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$18,999.91

15 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $18,815.40 12
EISAI INC. $104.51 1
Merck Sharp & Dohme Corporation $65.00 1
EMD Serono, Inc. $15.00 1

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREW POKLEPOVIC

NPI 1356550800 · CMS profile ID 515912

Allopathic & Osteopathic Physicians / Internal Medicine

RICHMOND, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356550800?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREW POKLEPOVIC, NPI 1356550800, CMS profile ID 515912. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356550800?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ANDREW POKLEPOVIC, NPI 1356550800, CMS profile ID 515912. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356550800?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ANDREW POKLEPOVIC, NPI 1356550800, CMS profile ID 515912, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1356550800?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

15 matching records · $18,999.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 15 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–15 of 15.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $150.0012/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651255609 CMS
E.R. Squibb & Sons, L.L.C. $500.0012/11/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651255615 CMS
E.R. Squibb & Sons, L.L.C. $4,310.0012/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651255611 CMS
E.R. Squibb & Sons, L.L.C. $124.9311/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651255607 CMS
E.R. Squibb & Sons, L.L.C. $4,310.0009/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651255595 CMS
E.R. Squibb & Sons, L.L.C. $102.4409/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651255593 CMS
EMD Serono, Inc. $15.0009/10/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702990075 CMS
EISAI INC. $104.5107/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697047577 CMS
Merck Sharp & Dohme Corporation $65.0006/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695888819 CMS
E.R. Squibb & Sons, L.L.C. $4,310.0005/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651255551 CMS
E.R. Squibb & Sons, L.L.C. $86.8904/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651255553 CMS
E.R. Squibb & Sons, L.L.C. $4,310.0004/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651255543 CMS
E.R. Squibb & Sons, L.L.C. $500.0003/26/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651255597 CMS
E.R. Squibb & Sons, L.L.C. $96.8803/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651255545 CMS
E.R. Squibb & Sons, L.L.C. $14.2601/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651255531 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $18,999.91 15
PY2020 $23,029.62 16
PY2021 $4,635.00 6
PY2022 $11,062.50 17
PY2023 $103.65 1
PY2024 $53.24 2
PY2025 $247.25 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $675,857.56 36
PY2024 Principal investigator $946,060.14 30
PY2023 Principal investigator $1,210,965.90 18
PY2022 Principal investigator $995,398.98 47
PY2021 Principal investigator $455,958.86 8
PY2020 Principal investigator $274,811.01 17
PY2019 Principal investigator $19,912.38 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $11,443.75 12/31/2025 Non-covered Recipient Entity
VCU Massey Cancer Center
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma# A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 1232925479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,452.00 12/19/2025 Non-covered Recipient Entity
VIRGINIA COMMONWEALTH UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184278858
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,267.44 11/26/2025 Non-covered Recipient Entity
VIRGINIA COMMONWEALTH UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184265557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,711.99 11/06/2025 Non-covered Recipient Entity
VIRGINIA COMMONWEALTH UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184257731
Principal investigator 1 Iovance Biotherapeutics, Inc. $4,004.10 11/05/2025 Non-covered Recipient Entity
Virginia Commonwealth University
101623 No dispute reported 06/30/2026 1252498483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,137.43 10/28/2025 Non-covered Recipient Entity
VIRGINIA COMMONWEALTH UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184253538
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,857.96 10/09/2025 Non-covered Recipient Entity
VIRGINIA COMMONWEALTH UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184248892
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,970.00 10/09/2025 Non-covered Recipient Entity
VIRGINIA COMMONWEALTH UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184248894
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,475.00 10/09/2025 Non-covered Recipient Entity
VIRGINIA COMMONWEALTH UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184248896
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,745.00 10/09/2025 Non-covered Recipient Entity
VIRGINIA COMMONWEALTH UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184248898
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,210.00 10/09/2025 Non-covered Recipient Entity
VIRGINIA COMMONWEALTH UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184248900
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,738.25 09/23/2025 Non-covered Recipient Entity
VIRGINIA COMMONWEALTH UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184241594
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,161.79 09/18/2025 Non-covered Recipient Entity
VIRGINIA COMMONWEALTH UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184240406
Principal investigator 1 Ascendis Pharma Endocrinology Inc $4,661.28 09/15/2025 Non-covered Recipient Entity
Virginia Commonwealth University
IL Believe No dispute reported 06/30/2026 1233997093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,450.24 08/26/2025 Non-covered Recipient Entity
VIRGINIA COMMONWEALTH UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184230631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,097.95 08/14/2025 Non-covered Recipient Entity
VIRGINIA COMMONWEALTH UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184228613
Principal investigator 1 Ascendis Pharma Endocrinology Inc $2,683.98 08/11/2025 Non-covered Recipient Entity
Virginia Commonwealth University
IL Believe No dispute reported 06/30/2026 1233996637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,281.64 07/31/2025 Non-covered Recipient Entity
VIRGINIA COMMONWEALTH UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184222752
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,738.25 07/10/2025 Non-covered Recipient Entity
VIRGINIA COMMONWEALTH UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184214324
Principal investigator 1 Merck Sharp & Dohme LLC $57,003.92 07/08/2025 Non-covered Recipient Entity
Virginia Commonwealth University
An open-label, randomized, Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic advanced melanoma No dispute reported 06/30/2026 1232931822
Principal investigator 1 Ascendis Pharma Endocrinology Inc $3,327.48 07/07/2025 Non-covered Recipient Entity
Virginia Commonwealth University
IL Believe No dispute reported 06/30/2026 1233996525
Principal investigator 1 Incyte Corporation $18,375.00 06/06/2025 Non-covered Recipient Entity
VIRGINIA COMMONWEALTH UNIVERSITY MASSEY CANCER CENTER
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1240615309
Principal investigator 1 Incyte Corporation $2,725.00 06/06/2025 Non-covered Recipient Entity
VIRGINIA COMMONWEALTH UNIVERSITY MASSEY CANCER CENTER
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1240615312
Principal investigator 1 Incyte Corporation $1,000.00 06/06/2025 Non-covered Recipient Entity
VIRGINIA COMMONWEALTH UNIVERSITY MASSEY CANCER CENTER
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1240615316
Principal investigator 1 Incyte Corporation $200,572.91 06/06/2025 Non-covered Recipient Entity
VIRGINIA COMMONWEALTH UNIVERSITY MASSEY CANCER CENTER
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1240615320
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,702.26 06/05/2025 Non-covered Recipient Entity
VIRGINIA COMMONWEALTH UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184204111
Principal investigator 1 Ascendis Pharma Endocrinology Inc $1,146.60 06/04/2025 Non-covered Recipient Entity
Virginia Commonwealth University
IL Believe No dispute reported 06/30/2026 1233995871
Principal investigator 1 Ascendis Pharma Endocrinology Inc $7,913.88 05/16/2025 Non-covered Recipient Entity
Virginia Commonwealth University
IL Believe No dispute reported 06/30/2026 1233995635
Principal investigator 1 Iovance Biotherapeutics, Inc. $22,525.00 05/07/2025 Non-covered Recipient Entity
Virginia Commonwealth University
117145 No dispute reported 06/30/2026 1252496139
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,210.00 05/07/2025 Non-covered Recipient Entity
Virginia Commonwealth University
117145 No dispute reported 06/30/2026 1252496141
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,672.10 04/25/2025 Non-covered Recipient Entity
Virginia Commonwealth University
101623 No dispute reported 06/30/2026 1252495889
Principal investigator 1 GlaxoSmithKline, LLC. $58,517.46 04/23/2025 Non-covered Recipient Entity
VIRGINIA COMMONWEALTH UNIVERSITY OFFICE OF SPONSORED PROGRAMS
0000000000000000000000000000000000000000000000000000000000000000214437 No dispute reported 06/30/2026 1192164472
Principal investigator 1 Iovance Biotherapeutics, Inc. $4,449.00 04/09/2025 Non-covered Recipient Entity
Virginia Commonwealth University
101623 No dispute reported 06/30/2026 1252496143
Principal investigator 1 Merck Sharp & Dohme LLC $157,600.00 04/08/2025 Non-covered Recipient Entity
Virginia Commonwealth University
An Open-Label Phase 1a,1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1232931870
Principal investigator 1 Merck Sharp & Dohme LLC $390.00 03/31/2025 Non-covered Recipient Entity
VCU Massey Cancer Center
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma# A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 1232925477
Principal investigator 1 Iovance Biotherapeutics, Inc. $10,638.90 02/12/2025 Non-covered Recipient Entity
Virginia Commonwealth University
101623 No dispute reported 06/30/2026 1252496467